Two recent studies have shown further evidence that antidepressant drugs can modulate central NLRP3 inflammasome activation, microglial structure and function (Pan et al., 2014; Du et al., 2016), thereby suggesting the therapeutic potential of targeting neuroinflammation to treat depression. This evidence concerns the gene NLRP3 and depressive symptom measurement.